The Institutional Biosafety Committee (IBC) is established by institutions that use biological agents in research. The IBC is responsible for oversight of all aspects of the institution’s program for biological agent use in research conducted at or on behalf of Northwell Health. The IBC ensures that research involving these agents is conducted in a manner that protects researchers, laboratory personnel, human research subjects, the public and the environment ensuring compliance with the NIH Guidelines federal and state regulations, and institutional policies.
Northwell Health has two authorized IBCs registered with the National Institutes of Health (NIH) Office of Biotechnology Activities (OBA) – Office of Science Policy reviewing basic science, pre-clinical, and clinical research using biological agents. These committees also function as the Institutional Review Entity (IRE) for research considered Dual Use Research of Concern (DURC).
Research involving biological agents requires:
- Registration and review by a health system authorized IBC and is conducted in accordance with determinations of the IBC; environmental, health and safety requirements; and other applicable requirements;
- Review by an Institutional Review Entity (IRE) for select agents if covered under the U.S. Government Policy for Dual Use Research of Concern (DURC);
- Training for all individuals involved in the conduct of the research, including those involved in the handling and management of biological agents.
Types of Biological Agents or Toxins Which Require Review by the IBC:
- Recombinant and synthetic nucleic acid molecules
- Potentially infectious or hazardous agents (bacteria, viruses, protozoans, fungi, prions, other microorganisms, and parasites)
- Biological Toxins
- Transgenic animals, invertebrates, and/or plants
- Artificial Gene Transfer
- Select Agents
- Synthetic Biology
- Dual Use Research of Concern (DURC)
Registrations are approved for a maximum 5-year period. Principal Investigators are required to conduct an annual self-assessment of their biological agent registrations and submit an update if there are any changes to approved registrations. IBC approval must be obtained prior to initiating any changes. The PI is responsible to ensure each member of the research team has access to the approved registration and that they are aware of their responsibility to ensure that biological agent use is conducted in accordance with the registration, Northwell and Institutional policy, and federal and state regulations.
|Northwell Health IBC Meetings|
|March 5, 2018
April 2, 2018
May 7, 2018
June 4, 2018
July 9, 2018
August 6, 2018
September 10, 2018
October 8, 2018
November 5, 2018
December 3, 2018
For questions regarding the Northwell Health IBC, please contact: